Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib (LOU064) in Moderate to Severe Sjögren's Syndrome
CTR20192371Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of remibrutinib in Sjögren's syndrome, sponsored by Novartis. Started Nov 2019; status: terminated.
02
Drugs
remibrutinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on CTR20192371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192371.